Preview: This page contains published external data. Original survey findings will be added when the 2026 GLP-1 Consumer Experience Survey is complete.
GLP-1 Cost & Financial Sacrifice Statistics (2026): The Hidden Price of Ozempic & Wegovy
GLP-1 medications rank among the most expensive prescription drugs in the United States, with brand-name list prices exceeding $1,000 per month. As demand surges, survey data reveals that many users make significant financial sacrifices to afford treatment — facing significant financial strain, and in some cases, discontinuing medication entirely due to cost.
This page compiles published pricing data and survey findings on GLP-1 financial burden from CMS, KFF, IQVIA, and GoodRx. All statistics are cited inline with their original source.
Data Sources at a Glance
5 Most Surprising Findings
$1,349/mo
Wegovy (semaglutide 2.4 mg) carries an average list price of approximately $1,349 per month before insurance or discounts
This represents the manufacturer's list price. Actual out-of-pocket costs vary significantly based on insurance coverage, copay cards, and pharmacy benefit structures.
~25%
of GLP-1 users said the drugs were 'very difficult' to afford
Financial strain was defined broadly to include difficulty paying bills, borrowing money, or reducing savings specifically due to GLP-1 medication expenses.
$27.5B
in gross Medicare Part D spending on GLP-1 medications in 2024
GLP-1 spending has grown rapidly — from $5.7B in 2022 to $27.5B in 2024 — making it one of the fastest-growing drug expenditure categories in the Medicare program.
Original Data Coming Soon
We are currently fielding the 2026 GLP-1 Consumer Experience Survey (n=500+, via Prolific) covering the 'golden handcuffs' effect — how GLP-1 medication costs influence employment and insurance decisions. Results will be published here in Q2 2026.
Want early access? Contact: [email protected]
82%
of U.S. adults say the cost of prescription drugs is unreasonable
This broader sentiment about drug pricing provides context for GLP-1 affordability concerns — dissatisfaction with prescription drug costs extends well beyond the GLP-1 user population.
What Do People Cut to Afford GLP-1s?
Original Data Coming Soon
We are currently fielding the 2026 GLP-1 Consumer Experience Survey (n=500+, via Prolific) covering specific financial sacrifices GLP-1 users make — cutting discretionary spending, reducing savings, delaying other medical care. Results will be published here in Q2 2026.
Want early access? Contact: [email protected]
Monthly Out-of-Pocket Costs
~$935/mo
Ozempic (semaglutide 1 mg) carries an average list price of approximately $935 per month
Ozempic is FDA-approved for type 2 diabetes, not weight loss, though it is frequently prescribed off-label for weight management. Insurance coverage for off-label use varies widely.
~$1,349/mo
Wegovy (semaglutide 2.4 mg) carries an average list price of approximately $1,349 per month
Variable
Employer-sponsored coverage of GLP-1 medications for obesity varies significantly by plan type, employer size, and state
Coverage rates differ widely. KFF's Employer Health Benefits Survey tracks insurance plan drug coverage trends, but exact percentages vary by firm size and year. Even plans that cover GLP-1s often require prior authorization.
Brand-Name vs Compounded: Cost Comparison
$150–$500/mo
Compounded semaglutide is available from telehealth providers at prices ranging from approximately $150 to $500 per month, depending on provider and dosage
Compounded versions are not FDA-approved and may differ in formulation from brand-name products. Pricing varies by compounding pharmacy, provider, and whether the product is sourced from a 503A or 503B pharmacy.
Original Data Coming Soon
We are currently fielding the 2026 GLP-1 Consumer Experience Survey (n=500+, via Prolific) covering financial sacrifice and cost management. Results will be published here in Q2 2026.
Want early access? Contact: [email protected]
GLP-1 "Golden Handcuffs": Staying in Jobs for Insurance
Original Data Coming Soon
We are currently fielding the 2026 GLP-1 Consumer Experience Survey (n=500+, via Prolific) covering how GLP-1 medication costs influence employment and insurance decisions. Results will be published here in Q2 2026.
Want early access? Contact: [email protected]
Original Data Coming Soon
We are currently fielding the 2026 GLP-1 Consumer Experience Survey (n=500+, via Prolific) covering financial sacrifice and cost management. Results will be published here in Q2 2026.
Want early access? Contact: [email protected]
Who Stops Due to Cost?
~25%
of GLP-1 users said the drugs were 'very difficult' to afford
Financial strain was associated with higher rates of discontinuation intent and lower reported satisfaction with treatment. Users without insurance coverage reported strain at significantly higher rates.
Original Data Coming Soon
We are currently fielding the 2026 GLP-1 Consumer Experience Survey (n=500+, via Prolific) covering financial sacrifice and cost management. Results will be published here in Q2 2026.
Want early access? Contact: [email protected]
Context: What Other Research Shows
82%
of U.S. adults say the cost of prescription drugs is unreasonable
This finding highlights that GLP-1 affordability concerns exist within a broader national frustration with prescription drug pricing.
$27.5B
in gross Medicare Part D spending on GLP-1 medications in 2024, making it one of the fastest-growing drug expenditure categories
GLP-1 spending has grown rapidly — from $5.7B in 2022 to $27.5B in 2024 — making it one of the fastest-growing drug expenditure categories in the Medicare program.
45M+
GLP-1 prescriptions were dispensed in the United States in 2023
The rapid growth in GLP-1 prescribing has created supply shortages and intensified debate about pricing and access.
What This Means
The financial data paints a picture of a treatment class that is clinically effective but economically burdensome for many users. With brand-name list prices exceeding $900 per month and insurance coverage inconsistent, a significant minority of GLP-1 users report making meaningful financial sacrifices to continue treatment.
The emergence of compounded semaglutide at lower price points ($150–$500/month) has created a parallel market that addresses cost barriers but raises questions about quality, oversight, and long-term availability.
Medicare spending reaching $27.5 billion on GLP-1s in a single year underscores the fiscal scale of this trend. As the user population grows, cost and access dynamics will likely intensify as both a personal financial issue and a systemic healthcare policy challenge.
Limitations
- List prices do not reflect actual out-of-pocket costs, which vary based on insurance, copay assistance programs, and pharmacy benefit structures.
- Financial strain data is self-reported and may be subject to recall bias or differing definitions of "strain" across surveys.
- Compounded semaglutide pricing varies significantly by provider and is subject to rapid change due to regulatory and supply factors.
- Insurance coverage data reflects point-in-time snapshots and may not capture the full complexity of prior authorization and step therapy requirements.
- Medicare spending figures include all GLP-1 indications (diabetes and obesity), not weight management alone.
- Some statistics previously reported on this page have been removed pending verification through our original survey research (Q2 2026). We prefer removing unverifiable claims to presenting uncertain data.
Frequently Asked Questions
How much does Ozempic or Wegovy cost per month without insurance?
Does insurance cover GLP-1 medications for weight loss?
Is compounded semaglutide significantly cheaper than brand-name?
How many people stop GLP-1 medications because of cost?
What are GLP-1 "golden handcuffs"?
Methodology
About Our Methodology
External statistics on this page are drawn from CMS Medicare Part D spending data, KFF Health Tracking Polls, IQVIA prescription dispensing reports, GoodRx pricing data, and Ro Health Surveys. All findings are cited inline with source and date. Original survey data from the 2026 GLP-1 Consumer Experience Survey (n=500+, Prolific-recruited) will be added as results become available.
Read full methodologyHow to Cite This Page
Suggested Citation (APA)
WeightLossProviderGuide.com. "GLP-1 Cost & Financial Statistics (2026): The Price of Weight Loss Medication." WeightLossProviderGuide.com, February 2026. https://weightlossproviderguide.com/research/glp1-cost-financial-statistics/
Topline data and future charts will be available under Creative Commons Attribution 4.0 (CC BY 4.0). Preferred attribution: “Source: GLP-1 Consumer Research (2026), weightlossproviderguide.com/research/.” A link is appreciated; nofollow is fine.